Inclusion of Polypills for Prevention of Cardiovascular Disease in the 23rd World Health Organization Model List of Essential Medicines: A Significant Step Towards Reducing Global Cardiovascular Morbidity and Mortality

Inclusion of Polypills for Prevention of Cardiovascular Disease in the 23rd World Health Organization Model List of Essential Medicines: A Significant Step Towards Reducing Global Cardiovascular Morbidity and Mortality

This commentary describes the potential impact of inclusion of polypills for prevention of cardiovascular disease in the 23rd WHO Model List of Essential Medicines, and provides a roadmap for adoption, implementation, sustainment, and scale-up. The World Health Organization’s endorsement of polypill...

Full description

Bibliographic Details
Main Authors:	Anubha Agarwal, Mark D. Huffman
Format:	Article
Language:	English
Published:	Ubiquity Press 2024-02-01
Series:	Global Heart
Subjects:	cardiovascular disease polypills world health organization essential medicines
Online Access:	https://account.globalheartjournal.com/index.php/up-j-gh/article/view/1310

Similar Items

Medicinal herbs: Potential polypills in cardiovascular diseases
by: Samaneh Noroozi, et al.
Published: (2021-04-01)

The feasibility of polypill for cardiovascular disease prevention in Asian Population
by: Apichard Sukonthasarn, et al.
Published: (2021-03-01)

Redefining the polypill: pros and cons in cardiovascular precision medicine
by: Siddharth Birla, et al.
Published: (2023-09-01)

Benefits of the Polypill on Medication Adherence in the Primary and Secondary Prevention of Cardiovascular Disease: A Systematic Review
by: Lopez-Lopez JP, et al.
Published: (2023-09-01)

Polypill Therapy for Cardiovascular Disease Prevention and Combination Medication Therapy for Hypertension Management
by: Keisuke Narita, et al.
Published: (2023-11-01)

Three-dimensional printing of flexible polypill
by: Yasir Karkar, et al.
Published: (2023-12-01)

Polypill Eligibility for Patients with Heart Failure with Reduced Ejection Fraction in the ASIAN-HF Registry: A Cross-Sectional Analysis
by: Aishwarya Vijay, et al.
Published: (2023-06-01)

Does the Polypill Improve Patient Adherence Compared to Its Individual Formulations? A Systematic Review
by: Ana Baumgartner, et al.
Published: (2020-02-01)

Economic Burden Associated with the Treatment with a Cardiovascular Polypill in Secondary Prevention in Spain: Cost-Effectiveness Results of the NEPTUNO Study
by: Cordero A, et al.
Published: (2023-07-01)

Simple, Accurate and Multianalyte Determination of Thirteen Active Pharmaceutical Ingredients in Polypills by HPLC-DAD
by: Barbara Żuromska-Witek, et al.
Published: (2022-12-01)

The use of the CNIC-Polypill in real-life clinical practice: opportunities and challenges in patients at very high risk of atherosclerotic cardiovascular disease – expert panel meeting report
by: Lilian Grigorian-Shamagian, et al.
Published: (2023-08-01)

Safety and efficacy of a cardiovascular polypill in people at high and very high risk without a previous cardiovascular event: the international VULCANO randomised clinical trial
by: José M. Mostaza, et al.
Published: (2022-12-01)

Evaluation of the polypill therapy effectiveness in patients with arterial hypertension and dyslipidemia who underwent COVID-19
by: V.E. Oleynikov, et al.
Published: (2024-03-01)

Hypertension and Hypercholesterolemia: is it Time for Anti-«Lipitensive» Therapy?
by: Z. D. Kobalava, et al.
Published: (2020-11-01)

3D Printed Mini-Floating-Polypill for Parkinson’s Disease: Combination of Levodopa, Benserazide, and Pramipexole in Various Dosing for Personalized Therapy
by: Hellen Windolf, et al.
Published: (2022-04-01)

World Heart Federation Roadmap for Secondary Prevention of Cardiovascular Disease: 2023 Update
by: Liliana Laranjo, et al.
Published: (2024-01-01)

Polypill for cardiovascular disease prevention.
by: Dalton, A
Published: (2013)

Cholesterol-Lowering Strategies for Cardiovascular Disease Prevention: The Importance of Intensive Treatment and the Simplification of Medical Therapy
by: Vincenzo Sucato, et al.
Published: (2024-03-01)

2023: The year in cardiovascular disease – the year of new and prospective lipid lowering therapies. Can we render dyslipidemia a rare disease by 2024?
by: Maciej Banach, et al.
Published: (2023-11-01)

RETRACTED ARTICLE:. WAYS TO IMPROVE TREATMENT EFFICIENCY OF PATIENTS WITH HIGH CARDIOVASCULAR RISK
by: G. A. Baryshnikova, et al.
Published: (2015-09-01)

Polypills with or without aspirin for primary prevention of cardiovascular disease
by: Mant, J, et al.
Published: (2021)

Therapy for hypertension and dyslipidemia: potential of Lipertans (on the example of a clinical observation)
by: V. V. Kashtalap
Published: (2022-12-01)

Rationale for a New Low-Dose Triple Single Pill Combination for the Treatment of Hypertension
by: Anthony Rodgers, et al.
Published: (2024-02-01)

Preferences of Healthcare Professionals on 3D-Printed Tablets: A Pilot Study
by: Odelia Goh, et al.
Published: (2022-07-01)

CLINICIAN — TREATS, AND PATIENT — BEING TREATED? RECENT VIEW ON THE TREATMENT ADHERENCE IN CORONARY HEART DISEASE SETTING
by: О. Yu. Shaydyuk, et al.
Published: (2017-10-01)

Antihypertensive Medication Regimens Used by US Adults With Hypertension and the Potential for Fixed‐Dose Combination Products: The National Health and Nutrition Examination Surveys 2015 to 2020
by: Catherine G. Derington, et al.
Published: (2023-06-01)

A quantitative comparison of essential cardiovascular medicines from countries in the Southern African Development Community to the WHO model essential medicines list
by: Ian Naicker, et al.
Published: (2022-12-01)

The Evolving Field of Acute Coronary Syndrome Management: A Critical Appraisal of the 2023 European Society of Cardiology Guidelines for the Management of Acute Coronary Syndrome
by: Roberto Licordari, et al.
Published: (2024-03-01)

The Role of Essential Oils and Their Main Compounds in the Management of Cardiovascular Disease Risk Factors
by: Jorge M. Alves-Silva, et al.
Published: (2021-06-01)

AHA Life's essential 8 and ideal cardiovascular health among young adults
by: Naman S. Shetty, et al.
Published: (2023-03-01)

Access to Essential Medicines and Diagnostic Tests for Cardiovascular Diseases in Maputo City, Mozambique
by: Neusa Jessen, et al.
Published: (2023-02-01)

The cardiovascular polypill as baseline treatment improves lipid profile and blood pressure regardless of body mass index in patients with cardiovascular disease. The Bacus study.
by: José Alejandro Chávez Fernández, et al.
Published: (2023-01-01)

Association of Cardiovascular Health Assessed by the New Life's Essential 8 Metrics With Years Lived Without Cardiovascular Disease
by: Xue Xia, et al.
Published: (2023-06-01)

Essential medicine list in India, 2022: A recent update
by: U. Sharath, et al.
Published: (2023-01-01)

Would primary healthcare professionals prescribe a polypill to manage cardiovascular risk? A qualitative interview study
by: Virdee, S, et al.
Published: (2013)

Polypill Brings Benefits to Patients with Cardiovascular Disease, Both Improving Medication Adherence and Demonstrating the Concept of Chronotherapy [Letter]
by: Zhu LL, et al.
Published: (2023-09-01)

Rationale and design of the Kanyini guidelines adherence with the polypill (Kanyini-GAP) study: a randomised controlled trial of a polypill-based strategy amongst Indigenous and non Indigenous people at high cardiovascular risk
by: Usherwood Tim, et al.
Published: (2010-08-01)

Non-essential heavy metal effects in cardiovascular diseases: an overview of systematic reviews
by: Saverio Nucera, et al.
Published: (2024-01-01)

Validation of “Life's Essential 8” Metrics With Cardiovascular Structural Status in Children: The PROC Study in China
by: Wen Shu, et al.
Published: (2023-06-01)

Association of Life's Essential 8 With Cardiovascular Disease and Mortality: The Framingham Heart Study
by: Athanasios Rempakos, et al.
Published: (2023-12-01)